Sigma Planning Corp’s Travere Therapeutics TVTX Stock Holding History

Sigma Planning Corp’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.07M	Buy	+35,090	New	+$2.14M	0.05%	338

Other funds holding TVTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return

OpenArc Corporate Advisory Atlanta, Georgia $8.86B AUM 19.31% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Sigma Planning Corp's TVTX Position: Q3 2026 in Review

Sigma Planning Corp opened a new position in Travere Therapeutics (TVTX) in Q3 2026: 35,090 shares worth $2.07M. The stake represents 0.05% of the portfolio and ranks #338 among its holdings.

35 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

Sigma Planning Corp held 35,090 shares of Travere Therapeutics worth $2.07M as of Q3 2026.
Travere Therapeutics was a new Sigma Planning Corp position in Q3 2026.
Travere Therapeutics made up 0.05% of Sigma Planning Corp's portfolio in Q3 2026, its #338 holding.
35 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Sigma Planning Corp's 13F filing for Q3 2026, filed 23 Oct 2026.